$9.72
+0.10%Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
OFIX โข NASDAQ
| Orthofix Medical Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
822.3M | 799.5M | 746.6M | 460.7M | 464.5M | 406.6M | 460M | 453M | 433.8M | 409.8M | 396.5M | 402.3M | 400.5M | 462.3M | 579M | 564.4M | 545.6M | 519.7M | 490.3M | 365.4M | |
GROSS PROFIT | ||||||||||||||||||||
(270.6M) | (253.6M) | (260.4M) | (123.5M) | (114.9M) | (101.9M) | (100.6M) | (96.6M) | (93M) | (87.9M) | (86.5M) | (98.9M) | (102.3M) | (86.5M) | (139.2M) | (131.7M) | (138.5M) | (152M) | (129M) | (93.6M) | |
551.7M | 545.9M | 486.3M | 337.2M | 349.6M | 304.7M | 359.3M | 356.4M | 340.8M | 321.9M | 310M | 303.4M | 298.2M | 375.8M | 439.8M | 432.7M | 407.2M | 367.7M | 361.3M | 271.7M | |
OPERATING INCOME | ||||||||||||||||||||
(620.2M) | (630.5M) | (625.4M) | (350.4M) | (357.9M) | (310.9M) | (378.1M) | (323.3M) | (302.5M) | (284.5M) | (291.6M) | (270.6M) | (271.2M) | (284.8M) | (350.8M) | (343.7M) | (343.3M) | (624.6M) | (302.3M) | (262.9M) | |
(456.4M) | (532.5M) | (530.4M) | (308.8M) | (290.7M) | (272.4M) | (309.3M) | (290M) | (272.8M) | (255.7M) | (265.2M) | (243.3M) | (241.7M) | (254.2M) | (320.1M) | (319.6M) | (304.8M) | (288.7M) | (259.9M) | (199M) | |
(57.1M) | (73.6M) | (80.2M) | (49.1M) | (49.6M) | (39.1M) | (34.6M) | (33.2M) | (29.7M) | (28.8M) | (26.4M) | (25M) | (26.8M) | (28.6M) | (25.1M) | (30.4M) | (31.5M) | (30.8M) | (24.2M) | (55M) | |
-68.5M | -84.6M | -139.1M | -13.3M | -8.3M | -6.3M | -18.8M | 30.1M | 40.8M | 21.1M | 9.3M | 17.1M | -5.1M | 89M | 32.5M | 89M | 63.9M | -256.9M | 38.1M | 8.9M | |
PRE-TAX INCOME | ||||||||||||||||||||
(17.5M) | (29.6M) | (8.6M) | (1.3M) | (1.8M) | (2.5M) | (122K) | (828K) | (416K) | (0.0) | (489K) | (1.8M) | (1.8M) | (4.2M) | (9.5M) | (17.2M) | (24.6M) | (20.2M) | (0.0) | (0.0) | |
-17.5M | -29.6M | -8.6M | -1.3M | -1.8M | -2.5M | -122K | -828K | -416K | 763K | -489K | -1.8M | -1.8M | -4.2M | -5.4M | -11.3M | -24.6M | -19.7M | 0.0 | 0.0 | |
(106.7M) | (24.3M) | (14.8M) | -7.4M | (17.6M) | -499K | (34.2M) | (0.0) | (0.0) | (0.0) | -259K | (0.0) | (490K) | (0.0) | (5.6M) | -6.3M | (7M) | (305M) | (18.2M) | (8.9M) | |
-22.3M | -39.3M | -9.6M | -4.4M | -5.2M | 5.9M | -8.3M | -7.2M | -4.4M | -2M | -748K | -4.7M | 589K | -7.1M | -33.9M | -11M | -23.9M | -38.1M | -23.3M | -2.5M | |
-90.8M | -123.9M | -148.7M | -17.7M | -13.5M | -368K | -27M | 22.9M | 36.4M | 19M | 8.5M | 12.5M | -6.5M | 82.7M | 20.7M | 72.4M | 40M | -295M | 14.8M | 6.3M | |
NET INCOME | ||||||||||||||||||||
(1.4M) | (2.1M) | (2.7M) | (2M) | (24.9M) | -2.9M | (1.4M) | (9.1M) | (29.1M) | (15.5M) | (10.8M) | (16.2M) | (9.2M) | (28.8M) | (21.8M) | (28.2M) | (15.5M) | -66.5M | (3.8M) | (13.4M) | |
-92.2M | -126M | -151.4M | -19.7M | -38.4M | 2.5M | -28.5M | 13.8M | 6.2M | 3.1M | -2.8M | -8.5M | -28.5M | 51.3M | -1.1M | 44.2M | 24.5M | -228.6M | 11M | -7M |
OFIX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 05, 2025 | June 30, 2025 | 2025 |
Continue your OFIX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.